Badía FJ, Arévalo MFG

Language: Spanish
References: 13
Page: 89-92
PDF size: 121.42 Kb.

ABSTRACT

Male patient 39 years old, who is being diagnosticated clinicaly and histopathologicaly of Eosinophilic Fasciitis with 3 months of evolution; his treatment began with prednisone 30 mg/d with relative advance, after a month and half, colchicine 1 mg/d and cyclosporine-A 200 mg/d are added, the last one was removed after 6 months as it was ineffective. Afterwards due to an exacerbation of symptoms, a therapeutic test begins with etanercept 25 mg given twice weekly as a subcutaneous injection, for five months without any benefit shown. After 29 months of evolution, last 8 without treatment, the cutaneous manifestation have diminished partially but melanosis, poikiloderma and dyskeratosis chances where shown; besides that, there is approximately 70% of recuperation in secondary articular limitation to the dermis tension. It is concluded that neither the cyclosporine-A treatment or etanercept, at the used dose, were capable to modify the natural clinical course of the sickness in this case.

REFERENCES

1. Shulman LE. Diffuse fasciitis with hypergammaglobulinemia and eosinophilia: a new syndrome? J Rheumatol 1974; Suppl 1: 46.

2. Rodnan GP, DiBartolomeo A, Medsger TA Jr. Eosinophilic fasciitis. Report of six cases of newly recognized scleroderma-like syndrome (abstract). Arthritis Rheum 1975; 18: 525.

3. Barnes I, Rodnan GP, Medsger TA, Short D. Eosinophilic fasciitis. A pathological study of twenty cases. Am J Pathol 1979; 96: 493-507.

4. Seibold JR, Rodnan GP, Medsger TA, Winkelstein A. Circulating immune complexes in eosinophilic fasciitis. Arthritis Rheum 1982; 25: 1180-1185.

5. Janin A, Socie G, Devergie A, Aractingi S, Esperon H, Verola O et al. Fasciitis in chronic graft-versus-host disease-a clinicopathologic study of 14 cases. Ann Intern Med 1994; 120: 993-998.

6. Toquet C, Hamidou MA, Renaudin K, Jarry A, Foulc P, Barbarot S et al. In situ immunophenotype of the inflammatory infiltrate in eosinophilic fasciitis. J Rheumatol 2003; 30: 1811-1815.

7. Shakoory B, Fistzgerald SM, Lee SA, Chi DS, Krishnaswamy G. The role of human mast cell-derived cytokines in eosinophil biology. J Interferon Cytokine Res 2004; 24(5): 271-281.

8. Varga L, Veli-Matti K. Eosinophilia-myalgia syndrome, eosinophilic fasciitis, and related fibrosing disorders. Curr Opin Rheumatol 1997; 9: 562-570.

9. Valencia IC, Chang A, Kirsner RS, Kerdel FA. Eosinophilic fasciitis responsive to treatment with pulsed steroid and cyclosporine. Int J Dermatol 1999; 38: 369-372.

10. Bukiej A, Dropinski J, Dyduch G, Szczeklik A. Eosinophilic fasciitis successfully treated with cyclosporine. Clin Rheumatol 2005; 24(6): 634-636.

11. Jaimes-Hernández J, Meléndez-Mercado C, Hernández-Díaz C. Fascitis eosinofílica, respuesta favorable con ciclosporina A. Primer Congreso Mexicano Canadiense de Reumatología. Reumatol Clin 2006; 2(1): 61.

12. Drosou A, Kirsner RS, Welsh E, Sullivan TP, Kerdel FA. Use of infliximab, an anti tumor necrosis alpha antibody, for inflammatory dermatoses. J Cutan Med Surg 2003; 7(5): 382-386.

13. Trallero-Araguas E, Selva O-Callaghan A, Simeón-Aznar CP, Sanjurjo-Golpe E, García-Patos V, Vilardell-Tarrés M. Fascitis eosinofílica: estudio de 10 pacientes. Med Clin (Barc) 2005; 125(4): 145-148.